01—Abstract
Summary
Summary of the 8-K filed February 12, 2020. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) announced on February 12, 2020, the pricing of a public offering of its common stock.
The company entered into an underwriting agreement to sell approximately 26.3 million shares at $19.00a per share, with an option for underwriters to purchase an additional 3.9 million shares. This offering is expected to generate significant proceeds for Moderna, estimated at around $478.1 million before expenses, and up to $549.9 million if the overallotment option is fully exercised. The net proceeds from this offering will provide Moderna with substantial capital, likely to be used for further research and development of its mRNA-based therapeutics and vaccines.
This move signals the company's intent to accelerate its pipeline and operational growth, leveraging the positive market sentiment towards its innovative platform. Investors should view this as a move to strengthen the company's financial position to fund its ambitious development programs.
02—Key points
Key Highlights
- Moderna priced a public offering of its common stock on February 11, 2020.
- The offering involves the sale of 26,315,790 shares at $19.00 per share.
- Underwriters have an option to purchase an additional 3,947,368 shares.
- Gross proceeds are estimated at approximately $478.1 million, potentially reaching $549.9 million if the option is exercised.
- The offering is being conducted under a Registration Statement on Form S-3.
- The offering is expected to close on or about February 14, 2020.
- The company issued a press release on February 11, 2020, announcing the pricing of the offering.
03—Questions
Frequently Asked Questions
What is the primary purpose of this stock offering?
The primary purpose of this stock offering is to raise capital for Moderna, Inc. The net proceeds are intended to fund the company's ongoing research and development activities for its mRNA-based therapeutics and vaccines, and potentially for general corporate purposes and working capital.
How much money does Moderna expect to raise from this offering?
Moderna estimates net proceeds of approximately $478.1 million from the sale of 26,315,790 shares. If the underwriters fully exercise their option to purchase an additional 3,947,368 shares, the total estimated net proceeds could reach approximately $549.9 million.
What is the significance of the $19.00 per share price?
The $19.00 per share price represents the public offering price, determined through negotiations between Moderna and the underwriters. For investors, this price sets the entry point for acquiring new shares in the company and reflects the market's valuation at the time of the offering.
When is the offering expected to be completed?
The offering is expected to close on or about February 14, 2020, subject to the satisfaction of customary closing conditions.
04—Continue